AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AVH

AVH - AVITA MEDICAL INC

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.12
Index:

Avita Medical is developing and marketing a range of regenerative skin products. It is headquartered in California and listed on the ASX and NASDAQ.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.215

30 Apr
2026

0.005

OPEN

$1.24

0.41%

HIGH

$1.27

353,677

LOW

$1.21

TARGET
$1.275 4.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
AVH: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 75.7 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-54.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx111.1 M
Book Value Per Share xxxxxxxxxxxxxxx-16.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-48.4 M
Net Profit Margin xxxxxxxxxxxxxxx-67.85 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-258.41 %
Return on Assets xxxxxxxxxxxxxxx-70.65 %
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-103.54 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-49.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx66 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx69 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx27 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.7 M
Capex % of Sales xxxxxxxxxxxxxxx1.54 %
Cost of Goods Sold xxxxxxxxxxxxxxx20 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx156 M
Research & Development xxxxxxxxxxxxxxx32 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

16/02/2026

1

Speculative Buy

$1.35

11.11%

Avita Medical’s FY25 result was broadly in line with forecasts by Morgans, with revenue slightly ahead and tighter costs reducing cash burn. Below-consensus FY26 sales guidance of US$80-85m is viewed as a constructive reset to rebuild credibility.

The broker believes reimbursement clarity removes a structural headwind, shifting focus to behavioural re-engagement by surgeons. Improved cost discipline is expected to provide operating leverage if revenue recovers.

Cash burn improved, highlight the analysts, and the funding runway was extended through a new debt facility, which modestly increased available liquidity.

The analyst makes no material forecast changes, retaining valuation assumptions. A Speculative Buy rating and target of $1.35 are maintained.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -23.35 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.29 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

20/04/2026

3

Hold

$1.25

2.88%

Canaccord Genuity maintains a Hold rating and $1.25 price target for Avita Medical following encouraging preliminary data for its Cohealyx dermal template. 

A prospective study showed a mean time-to-graft of 13.6 days for full-thickness skin defects, performing significantly faster than historical biologic matrix benchmarks.

3Q26 group revenue reached $3.2m, including a US sales debut of $300k across 115 units.

The broker remains cautious until final data regarding definitive closure times and infection resistance release in October 2026.

Normalised cash burn moderated this period with a $48m cash balance reported at quarter end.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -55.82 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -24.99 cents.
Access Extra Coverage Research History >

AVH STOCK CHART

FNArena News on AVH

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL: Buy Trigger Ahead

Apr 26 2022 - Technicals
2
Why CSL Fell Sharply Yesterday

Dec 17 2021 - Australia
3
Beating The Biotech Blues

Sep 14 2021 - International
4
Uncertainty Prevails For CSL

Aug 19 2021 - Australia
5
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
6
Wesfarmers On Drugs?

Jul 13 2021 - Australia
7
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
8
CSL: Buy The Dip

Jun 22 2021 - Technicals
9
CSL To Retest Its High?

May 25 2021 - Technicals
10
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest